Array BioPharma Inc. News Releases http://investor.arraybiopharma.com/ Array BioPharma Inc. News Releases en Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer http://investor.arraybiopharma.com/news-releases/news-release-details/array-biopharma-announces-braftovi-mektovi-cetuximab-meet - BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control - - BRAFTOVI + MEKTOVI + cetuximab reduced the risk of death by 48% versus control - - Potential to be the first chemotherapy-free, targeted regimen for metastatic CRC patients - - Array intends to Tue, 21 May 2019 08:00:00 -0400 Array BioPharma Inc. News Releases 16791 Array BioPharma to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference http://investor.arraybiopharma.com/news-releases/news-release-details/array-biopharma-present-bank-america-merrill-lynch-2019 BOULDER, Colo. , May 9, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas . The public is welcome to participate in the conference through Thu, 09 May 2019 16:05:00 -0400 Array BioPharma Inc. News Releases 16771 Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019 http://investor.arraybiopharma.com/news-releases/news-release-details/array-biopharma-reports-financial-results-third-quarter-17 - Net product sales of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. were $35.1 million in the third quarter - - BEACON CRC Phase 3 trial interim analysis remains on track to report out this quarter - - BRAFTOVI in combination with MEKTOVI and an anti-EGFR antibody recommended by the Tue, 07 May 2019 08:00:00 -0400 Array BioPharma Inc. News Releases 16751 Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019 http://investor.arraybiopharma.com/news-releases/news-release-details/array-biopharma-report-financial-results-third-quarter-fiscal-15 BOULDER, Colo. , April 30, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the third quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, May 7, 2019 at 9:00 am ET . Date:  Tuesday, May 7, 2019 Time: 9:00 a.m. Tue, 30 Apr 2019 16:05:00 -0400 Array BioPharma Inc. News Releases 16736 BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal http://investor.arraybiopharma.com/news-releases/news-release-details/braftovir-encorafenib-combination-mektovir-binimetinib-and BOULDER, Colo. , March 18, 2019 /PRNewswire/ --  Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network ® (NCCN ® ) has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include BRAFTOVI ® in combination with MEKTOVI ® Mon, 18 Mar 2019 08:00:00 -0400 Array BioPharma Inc. News Releases 16701 Array BioPharma to Present at the 39th Annual Cowen Health Care Conference http://investor.arraybiopharma.com/news-releases/news-release-details/array-biopharma-present-39th-annual-cowen-health-care-conference BOULDER, Colo. , March 5, 2019 /PRNewswire/ --  Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 39 th Annual Cowen Health Care Conference in Boston . The public is welcome to participate in the conference through a webcast on the Tue, 05 Mar 2019 16:05:00 -0500 Array BioPharma Inc. News Releases 16691 Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference http://investor.arraybiopharma.com/news-releases/news-release-details/array-biopharma-present-8th-annual-svb-leerink-partners-global BOULDER, Colo. , Feb. 21, 2019 /PRNewswire/ --  Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the SVB Leerink Partners 8 th Annual Global Healthcare Conference in New York.  The public is welcome to participate in the conference Thu, 21 Feb 2019 16:05:00 -0500 Array BioPharma Inc. News Releases 16671 Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019 http://investor.arraybiopharma.com/news-releases/news-release-details/array-biopharma-reports-financial-results-second-quarter-16 - Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million in net product sales, which represents quarter over quarter growth of 62% - - Combination of BRAFTOVI, MEKTOVI and ERBITUX® (cetuximab) demonstrated 15.3 months median overall survival in safety lead-in Tue, 05 Feb 2019 08:00:00 -0500 Array BioPharma Inc. News Releases 16601 Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019 http://investor.arraybiopharma.com/news-releases/news-release-details/array-biopharma-report-financial-results-second-quarter-17 BOULDER, Colo. , Jan. 29, 2019 /PRNewswire/ --  Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the second quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, February 5, 2019 . Ron Squarer, Chief Executive Officer, will lead the call. Tue, 29 Jan 2019 16:05:00 -0500 Array BioPharma Inc. News Releases 16571 Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer http://investor.arraybiopharma.com/news-releases/news-release-details/array-biopharma-announces-153-months-median-overall-survival - Data will be presented at ASCO 2019 Gastrointestinal Cancers Symposium - - Updated confirmed ORR remains 48% and updated median PFS remains 8.0 months - - Investor webcast will be held on Tuesday, January 15 at 9:00 AM ET - BOULDER, Colo. , Jan. 14, 2019 /PRNewswire/ -- Array BioPharma Inc. Mon, 14 Jan 2019 17:03:00 -0500 Array BioPharma Inc. News Releases 16536